Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Structural Variation Sequencing of 26 Amniotic Fluid Samples With Partial Gene Duplications and Postnatal Follow-Up of the Fetuses.

Prenatal diagnosis·2026

Same author

Engineered Lipid Nanoparticles with Promoted Endosomal Escape and R283S-Mediated Stimulator of Interferon Genes (STING) Activation for Pancreatic Cancer Immunotherapy.

Pharmaceutics·2026

Same author

An activatable naphthalimide-based fluorescent probe for hydrogen peroxide detection: visualizing microcystin-LR induced oxidative stress in zebrafish and hepatocyte injury mechanism.

The Analyst·2026

Same author

Dual-responsive polypyridyl Ru(II)-scaffolded hydrogel for trinitarian tumor therapy activated by mono-wavelength photo-irradiation.

Journal of nanobiotechnology·2026

Same author

Ratiometric Fluorescence and Smartphone-Assisted Visual Assay of Tetracycline and Levofloxacin Based on Dual-Emission Carbon Dots.

Luminescence : the journal of biological and chemical luminescence·2026

Same author

Dietary sublancin or oregano essential oil enhances growth and immunity in goat kids via modulating colonic microbiota and bile acids.

Animal nutrition (Zhongguo xu mu shou yi xue hui)·2026

Search research articles

Related Experiment Video

Updated: Jan 3, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A Bayesian Phase I/II Trial Design for Immunotherapy.

Suyu Liu¹, Beibei Guo², Ying Yuan³

¹Assistant Professor, Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009.

Journal of the American Statistical Association

|November 20, 2019

Summary

This summary is machine-generated.

This study introduces a novel Bayesian design for immunotherapy clinical trials, optimizing cancer treatment by balancing immune response, toxicity, and efficacy to find the best biologically active dose.

Keywords:

Bayesian adaptive design Immunotherapy dose finding immune response phase I/II trial risk-benefit tradeoff

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jan 3, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

Oncology
Biostatistics
Immunology

Background:

Immunotherapy represents a paradigm shift in cancer treatment, distinct from traditional chemotherapy.
Optimizing immunotherapy requires novel clinical trial designs that account for its unique biological mechanisms.

Purpose of the Study:

To propose a Bayesian phase I/II dose-finding design for immunotherapy.
To identify the biologically optimal dose by balancing immune response, toxicity, and efficacy.

Main Methods:

A Bayesian dose-finding design integrating immune response, toxicity, and efficacy.
Utilizing an Emax model for immune response and a latent variable approach for toxicity and efficacy.
Employing adaptive randomization based on accumulating patient data.

Main Results:

The proposed design effectively identifies the biologically optimal dose.
Demonstrates favorable operating characteristics for dose selection and patient allocation.
Successfully balances the risk-benefit tradeoff in immunotherapy trials.

Conclusions:

The novel Bayesian design offers a robust framework for optimizing immunotherapy dosing.
This approach facilitates personalized cancer treatment by maximizing therapeutic benefit while minimizing risk.
The design's adaptive nature enhances efficiency in identifying optimal immunotherapy doses.